

# Sam Schulman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6469297/sam-schulman-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

328  
papers

29,811  
citations

61  
h-index

170  
g-index

353  
ext. papers

34,820  
ext. citations

8.1  
avg, IF

7.09  
L-index



311	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 1	5.1	0
310	Recent Advances in Thrombosis and Hemostasis-Part VII. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2021</b> , 47, 621-622	5.3	0
309	MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. <i>BMJ Open</i> , <b>2021</b> , 11, e049557	3	
308	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. <i>Pilot and Feasibility Studies</i> , <b>2020</b> , 6, 52	1.9	3
307	Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2020</b> , 46, 772-776	5.3	30
306	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1004-1024	7	147
305	Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1143-1146	7	14
304	Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1495-1500	15.4	17
303	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1661-1671	15.4	6
302	Development of a standardized definition of pulmonary embolism-related death: A cross-sectional survey of international thrombosis experts. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1415-1420	15.4	7
301	Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability. <i>Blood</i> , <b>2020</b> , 136, 20-20	2.2	
300	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant-Reply. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 333-334	11.5	
299	Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease. <i>Tuberculosis and Respiratory Diseases</i> , <b>2020</b> , 83, 255-256	3.2	
298	COVID-19, hemostasis disorders and risk of thrombotic complications. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , <b>2020</b> , 75, 306-317	0.4	3
297	Recent Advances in Thrombosis and Hemostasis: Part VI. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2020</b> , 46, 863-864	5.3	0
296	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 936-945	2.4	8
295	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2020</b> , 46, 977-985	5.3	3
294	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , <b>2020</b> , 4, 4693-4738	7.8	187

293	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017316	6	5
292	Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. <i>TH Open</i> , <b>2020</b> , 4, e255-e262	2.7	0
291	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , <b>2020</b> , 4, 3520-3527	7.8	6
290	Is venous thromboembolism a preventable cause of death?. <i>Lancet Haematology</i> , <b>2020</b> , 7, e555-e556	14.6	2
289	Venous Thromboembolism in COVID-19. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1642-1653	7	25
288	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2950-2973	15.1	1682
287	Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1562-1568	15.4	20
286	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. <i>Blood Advances</i> , <b>2020</b> , 4, 1539-1553	7.8	6
285	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. <i>Blood Advances</i> , <b>2020</b> , 4, 500-513	7.8	5
284	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 499-506	15.4	5
283	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1144-1152	15.4	21
282	Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2019</b> , 45, 150-156	5.3	5
281	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 1469-1478	11.5	156
280	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1398-1399	15.4	
279	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , <b>2019</b> , 182, 12-19	8.2	5
278	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ</i> , <b>2019</b> , 366, l4363	5.9	83
277	Recent Advances in Thrombosis and Hemostasis-Part V. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2019</b> , 45, 757-759	5.3	
276	Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. <i>Blood Advances</i> , <b>2019</b> , 3, 158-167	7.8	71

275	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. <i>Anesthesiology</i> , <b>2019</b> , 131, 1153-1165	4.3	8
274	Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2125-2134	59.2	110
273	Treatment of bleeding complications in patients on anticoagulant therapy. <i>Blood</i> , <b>2019</b> , 133, 425-435	2.2	31
272	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , <b>2018</b> , 131, 2151-2160	2.2	38
271	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 282-290	5.1	22
270	Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 557-561	5.1	8
269	Management of recurrent venous thromboembolism in patients with cancer: A review. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S172-S177	8.2	12
268	Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 486-495	5.1	16
267	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 842-851	7	114
266	Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. <i>American Heart Journal</i> , <b>2018</b> , 195, 108-114	4.9	21
265	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , <b>2018</b> , 9, 176	4.2	34
264	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , <b>2018</b> , 132, 2527-2527	2.2	1
263	Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191137	3.7	9
262	Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study. <i>Blood</i> , <b>2018</b> , 132, 5060-5060	2.2	
261	Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 180-185	5.1	5
260	Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 37-44	2.8	9
259	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	9
258	Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. <i>Thrombosis Research</i> , <b>2018</b> , 171, 62-67	8.2	3

257	Splanchnic vein thrombosis: what are the long-term risks?. <i>Lancet Haematology</i> , <b>2018</b> , 5, e431-e432	14.6	2
256	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 684-688	5.1	42
255	Recent Advances in Thrombosis and Hemostasis - Part III. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 312-314	5.3	3
254	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. <i>Chest</i> , <b>2017</b> , 152, 81-91	5.3	53
253	Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. <i>Thrombosis Research</i> , <b>2017</b> , 152, 44-48	8.2	37
252	Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER, RE-COVERII, and RE-MEDY. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 484-489	5.1	3
251	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. <i>Blood</i> , <b>2017</b> , 129, 3285-3293	2.2	27
250	Bleeding Complications and Management on anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 886-892	5.3	7
249	Recent Advances in Thrombosis and Hemostasis-Part II. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 809-810	5.3	2
248	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2017</b> , 7, 16950	3	5
247	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 415-427	7	11
246	Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. <i>Blood</i> , <b>2017</b> , 130, 1706-1712	2.2	200
245	Direct Oral Anticoagulants in the Real World: Insights Into Appropriate Prescribing and Medication Use. <i>Canadian Journal of Nursing Research</i> , <b>2017</b> , 49, 105-107	1.5	4
244	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , <b>2017</b> , 89, 687-696	6.5	53
243	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2017</b> , 160, 97-104	8.2	11
242	Optimal timing of starting thromboprophylaxis for patients with acute spinal cord injury: A survey of Canadian spine surgeons. <i>Thrombosis Research</i> , <b>2017</b> , 160, 38-40	8.2	1
241	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2415-2424	7	45
240	Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 491-499	7	25

239	Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2045-2052	7	29
238	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1317-1325	7	14
237	Venous thromboembolism: Past, present and future. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1219-1229	7	47
236	Acute Unilateral Renal Infarction in the Setting of an Inherited Thrombophilia and Atrial Septal Defect. <i>Case Reports in Hematology</i> , <b>2017</b> , 2017, 3159363	0.7	
235	Recent Advances in Thrombosis and Hemostasis - Part I. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 805-807	5.3	1
234	Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER I, RE-COVER II, and RE-MEDY. <i>Vascular Medicine</i> , <b>2016</b> , 21, 506-514	3.3	43
233	Update on the Treatment of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 891-898	5.3	7
232	Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 714-21	7	13
231	Management of venous thromboembolism: an update. <i>Thrombosis Journal</i> , <b>2016</b> , 14, 23	5.6	25
230	Reply to Dr Lessire et al. <i>Regional Anesthesia and Pain Medicine</i> , <b>2016</b> , 41, 788	3.4	1
229	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , <b>2016</b> , 140, 81-88	8.2	10
228	Incidence and Risk Factors for Venous Thromboembolism in Patients with Spinal Cord Injury: A Retrospective Study. <i>Blood</i> , <b>2016</b> , 128, 1440-1440	2.2	
227	Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 291-8	7	18
226	Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2016</b> , 69, 449-453	0.5	4
225	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 480-5	7	4
224	Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. <i>Thrombosis Research</i> , <b>2016</b> , 145, 143-8	8.2	13
223	Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. <i>Regional Anesthesia and Pain Medicine</i> , <b>2016</b> , 41, 127-9	3.4	13
222	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , <b>2016</b> , 3, e267-75	14.6	36

221	Management of bleeding complications in patients with cancer on DOACs. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S142-7	8.2	8
220	Less menorrhagia for women with VTE. <i>Blood</i> , <b>2016</b> , 127, 1378-9	2.2	5
219	Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. <i>Thrombosis Research</i> , <b>2016</b> , 147, 97-101	8.2	15
218	Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 1369-1376	13.6	95
217	Thrombin generation test in children and adolescents with chronic liver disease. <i>Thrombosis Research</i> , <b>2015</b> , 135, 382-7	8.2	9
216	Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 513-9	9.4	12
215	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1474-80	11.5	131
214	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 823-33	59.2	719
213	Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery. <i>Thrombosis Research</i> , <b>2015</b> , 135, 841-5	8.2	4
212	Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 40, 430-6	5.1	8
211	Perioperative Management of Dabigatran: A Prospective Cohort Study. <i>Circulation</i> , <b>2015</b> , 132, 167-73	16.7	115
210	D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. <i>Annals of Internal Medicine</i> , <b>2015</b> , 162, 27-34	8	96
209	Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , <b>2015</b> , 3, 347-353.e1	3.2	20
208	Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 39, 427-33	5.1	13
207	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1010-8	15.4	60
206	Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 150-7	7	112
205	Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2015</b> , 41, 160-5	5.3	2
204	Activated prothrombin complex concentrate for dabigatran-associated bleeding. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 308-10	4.5	44

203	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2014</b> , 383, 880-8	40	322
202	Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. <i>Circulation</i> , <b>2014</b> , 129, 764-72	16.7	678
201	Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial. <i>Thrombosis Research</i> , <b>2014</b> , 134, 814-8	8.2	9
200	Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 1254-9	15.4	21
199	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , <b>2014</b> , 4, e005674	3	2
198	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , <b>2014</b> , 133 Suppl 2, S158-66	8.2	35
197	Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 233-9	7	39
196	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood</i> , <b>2014</b> , 124, 1968-75	2.2	491
195	Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 1137-41	7	36
194	Prolonged Bleeding After Surgery <b>2014</b> , 151-160		
193	When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth ?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2014</b> , 40, 852-9	5.3	13
192	Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2014</b> , 40, 99-105	5.3	36
191	Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". <i>Circulation</i> , <b>2014</b> , 130, e95	16.7	
190	Advantages and limitations of the new anticoagulants. <i>Journal of Internal Medicine</i> , <b>2014</b> , 275, 1-11	10.8	61
189	Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. <i>Obstetrics and Gynecology</i> , <b>2014</b> , 124, 600-609	4.9	47
188	New oral anticoagulant agents - general features and outcomes in subsets of patients. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 575-82	7	42
187	Venous thromboembolism in older adults: A community-based study. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 530-7.e3	2.4	32
186	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2014</b> , 37, 435-42	5.1	9

185	Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. <i>PLoS ONE</i> , <b>2014</b> , 9, e88131	3.7	6
184	Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. <i>Anesthesiology</i> , <b>2014</b> , 121, 969-77	4.3	57
183	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , <b>2013</b> , 26, 191-202	4.2	71
182	Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, 93-100	8	60
181	Adherence to anticoagulant treatment with dabigatran in a real-world setting. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 1295-9	15.4	78
180	Management and outcomes of major bleeding during treatment with dabigatran or warfarin. <i>Circulation</i> , <b>2013</b> , 128, 2325-32	16.7	222
179	Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1203-10	3.8	26
178	Tossing a coin or using common sense. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 432-4	15.4	2
177	New anticoagulants in atrial fibrillation management. <i>Thrombosis Research</i> , <b>2013</b> , 131 Suppl 1, S63-6	8.2	1
176	Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 709-18	59.2	693
175	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. <i>Thrombosis Research</i> , <b>2013</b> , 131, 300-3	8.2	2
174	Extended anticoagulation in venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 2329	59.2	8
173	Optimal duration of anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2013</b> , 39, 141-6	5.3	3
172	Bile acids and coagulation factors: paradoxical association in children with chronic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 152-8	2.2	14
171	Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1184-90	5.8	7
170	The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 566-7	15.4	
169	High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 184-90	7	14
168	Response to Dr Junqueira. <i>Chest</i> , <b>2013</b> , 143, 1191	5.3	1

167	Respiratory review of 2013: pulmonary thromboembolism. <i>Tuberculosis and Respiratory Diseases</i> , <b>2013</b> , 75, 89-94	3.2	5
166	Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 1136-1136	2.2	4
165	Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 212-212	2.2	10
164	Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 2375-2375 <sup>9</sup>	2.2	9
163	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , <b>2013</b> , 122, 460-460	2.2	2
162	Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 582-582	2.2	12
161	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. <i>Blood Transfusion</i> , <b>2013</b> , 11, 533-40	3.6	11
160	Perioperative Management Of Patients On Dabigatran In A Prospective Cohort Study. <i>Blood</i> , <b>2013</b> , 122, 3637-3637	2.2	
159	Advances in the management of venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , <b>2012</b> , 25, 361-77	4.2	8
158	Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. <i>Thrombosis Research</i> , <b>2012</b> , 129, 146-51	8.2	107
157	Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 493-8	7	41
156	How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. <i>Blood</i> , <b>2012</b> , 119, 3016-23	2.2	193
155	Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) FabR fragments (ThromboView <sup>®</sup> ) in the diagnosis of deep vein thrombosis: a phase II study. <i>Thrombosis Research</i> , <b>2012</b> , 130, 381-9	8.2	21
154	Is the warfarin saga over?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , <b>2012</b> , 42, 51-5	0.9	3
153	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1228-35	7	20
152	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e531S-e575S	5.3	763
151	Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e495S-e530S	5.3	687
150	Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, 53S-70S	5.3	177

149	Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e152S-e184S	5.3	920
148	Antithrombotic Therapy <b>2012</b> , 171-177		
147	Treatment of venous thromboembolism with dabigatran. <i>Current Opinion in Pulmonary Medicine</i> , <b>2012</b> , 18, 410-5	3	12
146	Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?. <i>Blood Coagulation and Fibrinolysis</i> , <b>2012</b> , 23, 705-13	1	4
145	The oral thrombin inhibitor dabigatran: strengths and weaknesses. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 7-15	5.3	15
144	Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e195S-e226S	5.3	1087
143	Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e601S-e636S	5.3	327
142	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , <b>2012</b> , 97, 1603-7	6.6	46
141	Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e278S-e325S	5.3	1402
140	Pharmacologic tools to reduce bleeding in surgery. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 517-21	3.1	10
139	Pharmacologic tools to reduce bleeding in surgery. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 517-521	3.1	24
138	Elevated Risk of Venous but Not Arterial Thrombosis in Waldenstro m $\beta$ Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 1603-1603	2.2	2
137	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , <b>2012</b> , 120, 19-19	2.2	6
136	Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etxilate Is Maintained Over 1 Year of Post-Treatment Follow-up. <i>Blood</i> , <b>2012</b> , 120, 21-21	2.2	8
135	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. <i>Blood</i> , <b>2012</b> , 120, 393-393	2.2	4
134	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Blood</i> , <b>2012</b> , 120, 499-499	2.2	3
133	Positive Predictive Value of Progressively Elevated D-Dimer Levels in Patients with a Suspected First Deep Vein Thrombosis.. <i>Blood</i> , <b>2012</b> , 120, 2258-2258	2.2	1
132	A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. <i>Drug Safety</i> , <b>2011</b> , 34, 449-63	5.1	15

131	Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. <i>Seminars in Hematology</i> , <b>2011</b> , 48, 46-54	4	10
130	A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 232-8	7	9
129	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. <i>BMJ, The</i> , <b>2011</b> , 342, d3036	5.9	234
128	Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. <i>Blood</i> , <b>2011</b> , 117, 2089-92	2.2	13
127	Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2011</b> , 155, 653-9, W201-3 <sup>8</sup>		69
126	Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: no. <i>Stroke</i> , <b>2011</b> , 42, 3663-4	6.7	15
125	A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , <b>2011</b> , 118, 205-205	2.2	41
124	New aspects on treatment modalities for thromboembolic episodes. <i>Journal of Internal Medicine</i> , <b>2010</b> , 268, 109-19	10.8	2
123	Oral vitamin K effectively treats international normalized ratio (INR) values in excess of 10. Results of a prospective cohort study. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 118-21	7	29
122	Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 652-60	5.8	59
121	Optimal timing of resumption of warfarin after intracranial hemorrhage. <i>Stroke</i> , <b>2010</b> , 41, 2860-6	6.7	151
120	Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. <i>Thrombosis Research</i> , <b>2010</b> , 125, 393-7	8.2	10
119	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 2499-510	59.2	2240
118	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , <b>2010</b> , 115, 4991-8	2.2	158
117	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 202-4	15.4	566
116	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 641-50	15.4	11
115	Direct and indirect costs of management of long-term warfarin therapy in Canada. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 2192-200	15.4	30
114	Dabigatran etexilate: future directions in anticoagulant treatment. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2009</b> , 15 Suppl 1, 32S-41S	3.3	5

113	STUDIES ON THE MEDICAL TREATMENT OF DEEP VEIN THROMBOSIS. <i>Acta Medica Scandinavica</i> , <b>2009</b> , 218, 3-68		
112	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 579-83	7.1	12
111	The plasma concentration of activated protein C appears normal in patients with haemophilia. <i>Haemophilia</i> , <b>2009</b> , 15, 566-70	3.3	4
110	Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2009</b> , 32, 378-82	1.6	77
109	Getting intimate with the venous thrombus. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 1266-7	15.4	6
108	Cervical artery dissection: pathology, epidemiology and management. <i>Thrombosis Research</i> , <b>2009</b> , 123, 810-21	8.2	114
107	Dabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2342-52	59.2	1914
106	Rivaroxaban in orthopedic surgery--a change of paradigm?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2009</b> , 15, 613-20	3.3	1
105	Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 293-300	8	106
104	Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.. <i>Blood</i> , <b>2009</b> , 114, 1-1	2.2	1
103	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. <i>Blood</i> , <b>2009</b> , 114, 1872-1872	2.2	2
102	Anticoagulants for the Treatment of Venous Thromboembolism. <i>Fundamental and Clinical Cardiology</i> , <b>2009</b> , 155-170		
101	Validation of a composite score for clinical severity of hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1113-21	15.4	71
100	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , <b>2008</b> , 263, 412-9	10.8	10
99	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 257S-298S	5.3	549
98	Current strategies in prophylaxis and treatment of venous thromboembolism. <i>Annals of Medicine</i> , <b>2008</b> , 40, 352-9	1.5	9
97	Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 762-71	5.3	3
96	Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. <i>Haematologica</i> , <b>2008</b> , 93, 1273-5	6.6	5

95	Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 99, 616-22	7	30
94	Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. <i>Thrombosis Journal</i> , <b>2008</b> , 6, 15	5.6	22
93	Anticoagulants and their reversal. <i>Transfusion Medicine Reviews</i> , <b>2007</b> , 21, 37-48	7.4	160
92	Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2007</b> , 4, 472-3		
91	The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 766-74	8	151
90	Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 657-60	1	22
89	NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 264-72	2.9	5
88	Optimal reversal of vitamin K antagonists. <i>Thrombosis Research</i> , <b>2007</b> , 119, 15-6	8.2	5
87	The onerous task of comparing treatments in inhibitor patients. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 98, 710-712	7	2
86	Thromboprophylaxis in medical patients--why not for all?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2006</b> , 35, 141-5		3
85	Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2006</b> , 3, 358-9		0
84	Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 1813-23	2.5	13
83	Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. <i>Lancet, The</i> , <b>2006</b> , 368, 371-8	40	236
82	New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 258-66	7	24
81	Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 734-42	15.4	342
80	Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. <i>British Journal of Haematology</i> , <b>2006</b> , 133, 68-77	4.5	9
79	An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. <i>Haemophilia</i> , <b>2006</b> , 12, 223-7	3.3	25
78	The role of ximelagatran in the treatment of venous thromboembolism. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2005</b> , 34 Suppl 1, 18-24		6

77	Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. <i>Country Review Ukraine</i> , <b>2005</b> , 7, C34-C40		12
76	Recombinant FVIIa in children with liver disease. <i>Thrombosis Research</i> , <b>2005</b> , 116, 185-97	8.2	20
75	Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 279-90	6.1	21
74	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 692-4	15.4	2787
73	Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 1177-80	7	22
72	Ximelagatran in the clinic: practical management of patients. <i>Seminars in Vascular Medicine</i> , <b>2005</b> , 5, 301-7		
71	A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran. <i>Seminars in Vascular Medicine</i> , <b>2005</b> , 5, 259-65		2
70	Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 522-527	7	7
69	Patient self-management of anticoagulants reduced arterial thromboembolism and adverse effects. <i>ACP Journal Club</i> , <b>2005</b> , 143, 8		
68	Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 820-4	7	10
67	Minimizing factor requirements for surgery without increased risk. <i>Haemophilia</i> , <b>2004</b> , 10 Suppl 4, 35-40	3.3	6
66	Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 287S-310S	5.3	361
65	Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data.. <i>Blood</i> , <b>2004</b> , 104, 710-710	2.2	2
64	Clinical practice. Care of patients receiving long-term anticoagulant therapy. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 675-83	59.2	183
63	Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1713-21	59.2	365
62	Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2003</b> , 29 Suppl 1, 33-6	5.3	3
61	Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 679-87	7	47
60	Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 215-25	7	10

59	Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 89, 741-6	7	2
58	Low-intensity warfarin therapy prevented recurrent venous thromboembolism. <i>ACP Journal Club</i> , <b>2003</b> , 139, 42		
57	Low-intensity warfarin therapy prevented recurrent venous thromboembolism. <i>ACP Journal Club</i> , <b>2003</b> , 139, 42		
56	Pregnancy, Heparin and Osteoporosis. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 180-181	7	26
55	Inhibition of warfarin activity by ribavirin. <i>Annals of Pharmacotherapy</i> , <b>2002</b> , 36, 72-4	2.9	30
54	Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 29, 441-9	3.1	70
53	Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?. <i>Blood</i> , <b>2002</b> , 99, 2271-2	2.2	33
52	Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. <i>The Hematology Journal</i> , <b>2002</b> , 3, 311-4		2
51	Pregnancy, heparin and osteoporosis. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 180-1	7	4
50	Duration of anticoagulants in acute or recurrent venous thromboembolism. <i>Current Opinion in Pulmonary Medicine</i> , <b>2000</b> , 6, 321-5	3	3
49	Molecular genetic analysis of severe protein C deficiency. <i>Human Genetics</i> , <b>2000</b> , 106, 646-653	6.3	10
48	Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1953-8	59.2	282
47	Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2000</b> , 26, 421-4	5.3	28
46	Molecular genetic analysis of severe protein C deficiency. <i>Human Genetics</i> , <b>2000</b> , 106, 646-53	6.3	30
45	The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 81, 684-689	7	184
44	Safety and Efficacy of Continuous Infusion of a Combined Factor VIII/von Willebrand Factor (vWF) Concentrate (Haemate-P) in Patients with von Willebrand Disease. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 81, 229-233	7	41
43	For how long should the treatment with vitamin K antagonists be maintained?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1999</b> , 29 Suppl S1, 89-90		
42	Optimization of treatment for venous thromboembolism and prevention of recurrences. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1999</b> , 29 Suppl S1, 79-80		

41	Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. <i>British Journal of Haematology</i> , <b>1999</b> , 105, 1109-13	4.5	226
40	Major surgery seems not to influence HIV disease progression in haemophilia patients. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 10-4	4.5	5
39	Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. <i>American Journal of Medicine</i> , <b>1998</b> , 104, 332-8	2.4	414
38	Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1998</b> , 28 Suppl 3, 17-21		1
37	The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 393-8	59.2	490
36	Coagulation factor concentrates by continuous infusion. <i>Transfusion Medicine Reviews</i> , <b>1997</b> , 11, 56-63	7.4	16
35	Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 693-698	7	16
34	Increased fetal loss in women with heritable thrombophilia. <i>Lancet, The</i> , <b>1996</b> , 348, 913-6	40	550
33	Anticoagulation in venous Thrombosis. <i>Journal of the Royal Society of Medicine</i> , <b>1996</b> , 89, 624-630	2.3	5
32	Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. <i>Clinical Orthopaedics and Related Research</i> , <b>1996</b> , 65-75	2.2	39
31	The fixed flexed and subluxed knee in the haemophilic child: what should be done?. <i>Haemophilia</i> , <b>1996</b> , 2, 47-50	3.3	18
30	The feasibility of using concentrates containing factor IX for continuous infusion. <i>Haemophilia</i> , <b>1995</b> , 1, 103-10	3.3	24
29	A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1661-5	59.2	764
28	Social support and the development of immune function in human immunodeficiency virus infection. <i>Psychosomatic Medicine</i> , <b>1995</b> , 57, 32-6	3.7	78
27	Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. <i>Acta Haematologica</i> , <b>1995</b> , 94 Suppl 1, 35-42	2.7	24
26	Hepatitis E virus infection in hemophiliacs. <i>Journal of Medical Virology</i> , <b>1995</b> , 46, 153-6	19.7	25
25	Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 486-492	7	41
24	Stability of factor VIII concentrates after reconstitution. <i>American Journal of Hematology</i> , <b>1994</b> , 45, 217-231	7.3	57

23	Psychosocial self-prognosis in relation to mortality and morbidity in hemophiliacs with HIV infection. <i>Psychotherapy and Psychosomatics</i> , <b>1994</b> , 62, 185-92	9.4	19
22	Coping style in relation to the consumption of factor concentrate in HIV-infected hemophiliacs during the years after their infection became known. <i>Psychotherapy and Psychosomatics</i> , <b>1994</b> , 61, 205-10 <sup>4</sup>		
21	The Effectiveness of Desmopressin in Patients with Disorders of Primary Haemostasis <b>1993</b> , 161-167		1
20	Two different missense mutations at Arg 178 of the protein C (PROC) gene causing recurrent venous thrombosis. <i>Human Genetics</i> , <b>1992</b> , 89, 685-6	6.3	7
19	Effects of factor VIII concentrates on the immune system in hemophilic patients. <i>Annals of Hematology</i> , <b>1991</b> , 63, 145-51	3	15
18	DDAVP--the multipotent drug in patients with coagulopathies. <i>Transfusion Medicine Reviews</i> , <b>1991</b> , 5, 132-44	7.4	32
17	Heparin, DDAVP and the Bleeding Time. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 65, 242-244	7	28
16	Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1990</b> , 22, 393-7		26
15	Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants. <i>Acta Medica Scandinavica</i> , <b>1988</b> , 224, 425-30		9
14	HIV-serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. <i>European Journal of Haematology</i> , <b>1988</b> , 41, 459-66	3.8	9
13	No evidence for vertical transmission in children born to HIV seropositive male haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1988</b> , 20, 141-3		
12	HIV isolation and antigen detection in infected individuals and their seronegative sexual partners. <i>Aids</i> , <b>1988</b> , 2, 107-11	3.5	9
11	Pulmonary hypertension in hemophilia. <i>Annals of Internal Medicine</i> , <b>1988</b> , 109, 759-60	8	12
10	HIV infection in a defined population of Swedish haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1987</b> , 19, 159-66		8
9	Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase. <i>Acta Medica Scandinavica</i> , <b>1986</b> , 219, 349-57		58
8	Transmission of HIV infection to heterosexual partners but not to household contacts of seropositive haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1986</b> , 18, 497-500		20
7	Relationship Between Thromboembolic Complications and Intensity of Treatment During Long-Term Prophylaxis with Oral Anticoagulants Following DVT. <i>Thrombosis and Haemostasis</i> , <b>1985</b> , 53, 137-140	7	18
6	Hepatitis, epidemiology and liver function in hemophiliacs in Sweden. <i>Acta Medica Scandinavica</i> , <b>1984</b> , 215, 249-56		14

5	Local venous infusion of streptokinase in DVT. <i>Thrombosis Research</i> , <b>1984</b> , 34, 213-6	8.2	8
4	A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the Thigh. <i>Thrombosis and Haemostasis</i> , <b>1984</b> , 51, 261-265	7	4 <sup>o</sup>
3	Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>1984</b> , 52, 276-280	7	19
2	Thermography in the Diagnosis of DVT. <i>Thrombosis and Haemostasis</i> , <b>1981</b> , 46, 652-654	7	5
1	Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study. <i>BMJ</i> , <i>The</i> ,e067378	5.9	4